Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. ##STR00001##

Guo; Liangqin

Hagmann; William K.

He; Shuwen

Lai; Zhong

Liu; Jian

Nargund; Ravi P.

Shah; Shrenik K.

Truong; Quang T.

Merck Sharp &amp; Dohme Corp

Oxadiazole beta carboline derivatives as antidiabetic compounds

Novel substituted polyhydro-.beta.-carboline derivatives useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotic agents are disclosed. Further the compounds are antianxiety agents and antiulcer agents. Further, the compounds are useful for treating and/or preventing panic attacks. They are agents useful for preventing the response to withdrawal from chronic treatment with or use of nicotine, caffeine, diazepam, alcohol, cocaine or opioids. Also disclosed are pharmaceutical compositions and methods of treatment using the compounds as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds in diagnostic compositions.

Warner-Lambert Company

N-substituted cycloalkyl and polycycloalkyl polyhydro-.beta.-carboline-phenylalanine- and phenethylamine derivatives

beta carboline

offita

obesity

beta carboline/offita

Oxadiazole beta carboline derivatives as antidiabetic compounds

N-substituted cycloalkyl and polycycloalkyl polyhydro-.beta.-carboline-phenylalanine- and phenethylamine derivatives

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum